Here, we aimed to assess the relationship between STING subtypes and tumor immunogenicity in SCLC and observed markedly higher expression of immune‐related genes, including HLAs and immune checkpoints, in STING‐high compared with STING‐low SCLC tumors (Figure 3A). This evidence concerns the gene STING1 and neoplasm.